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60 Years of Cardiothoracic Surgery at Jefferson: From the
Heart-Lung Machine to the ‘Portable’ Total Artificial Heart
Continued innovation in
treating advanced heart failure

Surgeon Speaks

The Cardiac Transplantation and
Mechanical Circulatory Support
Program, led by director John Entwistle,
III, MD, PhD, offers several leadingedge treatment options to patients
with advanced heart failure. Options
include the latest-generation left
ventricular assist devices (LVADs) and
the SynCardia temporary Total Artificial
Heart (TAH).

John H. Gibbon, Jr., MD, poses with his “Model II” heart-lung machine on the tenth anniversary of the
world’s first successful extracorporeal cardiac surgery. On May 6, 1953 at Jefferson Medical College
Hospital, Dr. Gibbon and his staff, closed a very serious septal defect between the upper chambers of
the heart of eighteen-year-old Cecelia Bavolek. Ms. Bavolek was connected to the device for threequarters of an hour and for 26 crucial minutes she totally depended upon the machine’s artificial
cardiac and respiratory functions. (Images courtesy of Thomas Jefferson University Archives, Scott
Memorial Library.)

On May 6, 1953, John H. Gibbon,
Jr., MD – the third Samuel D. Gross
Professor and Chair of the Department
of Surgery (1946–1967) and Director
of Experimental Surgery at Jefferson –
performed the first successful surgery
with the groundbreaking heart-lung
machine he developed. With this
operation, Dr. Gibbon launched a new
era in cardiac surgery.
As we commemorate the 60th
anniversary of Dr. Gibbon’s
milestone, patients of the Division of
Cardiothoracic Surgery continue to
benefit from Jefferson’s commitment
to continual innovation under the
leadership of James Diehl, MD, FACS,
and two highly specialized programs.

State-of-the-art life support

The Adult Extracorporeal Membrane
Oxygenation (ECMO) Program boasts
survival rates that far exceed reported
national rates. Established in 2010 by

In this issue

Nicholas Cavarocchi, MD, FACS, FCCP,
Director of the Cardiac and Vascular
Intensive Care Unit, the program’s
leading-edge equipment provides both
cardiac and respiratory support (oxygen)
to individuals with severely diseased or
damaged heart and lungs.
At present, Jefferson is the only hospital
in the area to utilize two transport
devices – the SERVO-i ventilator and
the CARDIOHELP (portable) ECMO
machine. Using these devices, the
Jefferson ECMO team (comprised of
physicians and mid-level providers in
the Cardiac ICU, JeffSTAT medical
transportation staff, and respiratory
therapists) is able to transport critically
ill patients and place patients on
ECMO before they are transferred to
Jefferson. By placing patients on ECMO
earlier than usual, we improve their
chances of being successfully weaned
from ECMO or having surgery with
fewer complications.

In 2012, the program acquired the
SynCardia TAH device, which now
boasts a mobile software driver (just
recently approved by the FDA) to
operate the device outside of a hospital
setting. This allows some patients
awaiting a heart transplant to return
home and, in some cases, resume their
normal activities.
Treatment options for end-state heart
failure are a permanent LVAD, LVAD
as a bridge to transplant, or a heart
transplant. But LVAD options are viable
only for patients with failure of the left
side of the heart. For those with failure
of the right side or both sides of the heart,
and for those with cardiac amyloidosis
(“stiff heart syndrome”), there has not
been a good option for returning patients
home. SynCardia’s portable driver should
change that, and Jefferson is working to
identify an optimal candidate for the first
implant procedure.
“Because of these advanced therapies –
from the SynCardia TAH device and
our LVAD capabilities to our unique
ECMO equipment – Jefferson is able
to successfully treat a sicker group of
patients who otherwise would have a
very poor prognosis,” concludes Dr.
Diehl. “We are honored to continue
Dr. Gibbon’s legacy of innovative
patient care.”
A lecture on May 2nd will highlight
the anniversary – see page 4.

Dr. Entwistle demonstrates the orientation
of a Left Ventricular Assist Device.

“The surgical options for treating advanced
heart failure are continually evolving. In
addition to the introduction of new devices,
such as the SynCardia Total Artificial Heart,
we’re finding new ways to manage patients
previously thought untreatable.
“For example, Jefferson is joining heart
centers across the country in learning
how to better select patients for the Left
Ventricular Assist Device (LVAD). Historically,
patients with heart failure had not explored
surgical treatments until their condition had
progressed significantly. Thus, most patients
receiving the LVAD were quite sick.
“Today, we’re discovering that if we can
catch some patients earlier in the process, we
can obtain better results. For certain patients,
the LVAD pump can support a high quality
of life. In fact, I’ve had patients who have
traveled abroad with the pump and others
who have able to get back to work just a few
months after surgery.”
John Entwistle, III, MD, PhD
Surgical Director, Cardiac Transplantation
and Mechanical Circulatory Support,
and Associate Professor of Surgery
To learn more visit:
www.jeffersonhospital.org/cardiothoracic
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